WTA
CGEM icon

Washington Trust Advisors’s Cullinan Oncology CGEM Stock Holding History

Washington Trust Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-127
Closed -$956 – 696
2025
Q2 		$956 Hold
127
– – ﹤0.01% 626
2025
Q1 		$961 Hold
127
– – ﹤0.01% 630
2024
Q4 		$1.55K Hold
127
– – ﹤0.01% 627
2024
Q3 		$2.13K Hold
127
– – ﹤0.01% 633
2024
Q2 		$2.21K Hold
127
– – ﹤0.01% 628
2024
Q1 		$2.17K Hold
127
– – ﹤0.01% 637
2023
Q4 		$1.29K Hold
127
– – ﹤0.01% 654
2023
Q3 		$1.15K Hold
127
– – ﹤0.01% 659
2023
Q2 		$1.37K Buy
127
+56
+79% +$595 ﹤0.01% 642
2023
Q1 		$727 Hold
71
– – ﹤0.01% 766
2022
Q4 		$749 Hold
71
– – ﹤0.01% 771
2022
Q3 		$1K Hold
71
– – ﹤0.01% 876
2022
Q2 		$1K Hold
71
– – ﹤0.01% 907
2022
Q1 		$1K Hold
71
– – ﹤0.01% 974
2021
Q4 		$1K Buy
+71
New +$1.42K ﹤0.01% 978

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Washington Trust Advisors's CGEM Position: Q3 2025 in Review

Washington Trust Advisors sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 127 shares — an estimated $956 sold.

Washington Trust Advisors first reported a position in CGEM in Q4 2021 and held it in 15 quarters. The position peaked at $2.21K in Q2 2024. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Washington Trust Advisors reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • Washington Trust Advisors sold 127 Cullinan Oncology shares in Q3 2025, an estimated $956.
  • Washington Trust Advisors first reported a position in Cullinan Oncology in Q4 2021 and held it in 15 quarters.
  • Washington Trust Advisors's Cullinan Oncology position peaked at $2.21K in Q2 2024.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Washington Trust Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.